Zanidatamab (Anti-ERBB2 / HER2 / CD340) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). It has anti-tumour activity and can be used in treatment of HER2-positive breast and gastric cancer. MW :144.96 KD.